There is a Phase I clinical trial for a new treatment for relapsed/refractory multiple myeloma (RRMM) called P-BCMA-ALLO1. This treatment is an allogeneic CAR-T therapy, meaning it is made from healthy donor T-cells rather than the patient’s own cells. This “off-the-shelf” approach offers potential advantages over traditional CAR-T therapies, which are personalized and can be expensive and time-consuming to produce.

P-BCMA-ALLO1 targets the B-cell maturation antigen (BCMA) found on myeloma cells. The treatment uses Poseida Therapeutics’s piggyBac® DNA Delivery System to introduce a CAR that targets BCMA, as well as a safety switch. The trial showed a remarkable 91% overall response rate (ORR) among 23 heavily pretreated patients. This response rate is particularly noteworthy given that many patients had aggressive disease and would not have qualified for standard autologous CAR-T therapy. The treatment also demonstrated a good safety profile. Based on these promising results, the therapy is advancing to a Phase Ib trial.

Source